BRIEF-FDA Grants Priority Review for Biologics License Application (BLA) and EMA Accepts Marketing Authorisation Application (MAA) for Apitegromab as a Treatment for Spinal Muscular Atrophy

Reuters

25 Mar

BRIEF-FDA Grants Priority Review for Biologics License Application <a href="https://laohu8.com/S/BLA.AU">$(BLA.AU)$</a> and EMA Accepts Marketing Authorisation Application <a href="https://laohu8.com/S/MAA">$(MAA)$</a> for Apitegromab as a Treatment for Spinal Muscular Atrophy

March 25 (Reuters) - Scholar Rock Holding Corp SRRK.O:

FDA GRANTS PRIORITY REVIEW FOR BIOLOGICS LICENSE APPLICATION (BLA) AND EMA ACCEPTS MARKETING AUTHORISATION APPLICATION (MAA) FOR APITEGROMAB AS A TREATMENT FOR SPINAL MUSCULAR ATROPHY
SCHOLAR ROCK HOLDING CORP - FDA PDUFA DATE FOR APITEGROMAB SET FOR SEPTEMBER 22, 2025
SCHOLAR ROCK HOLDING CORP - PLANS U.S. COMMERCIAL LAUNCH IN 2025

Source text: ID:nBw1KGRFLa

Further company coverage: SRRK.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2522602952"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2522602952\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2522602952?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-03-25 19:33","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2522602952","market":"us","top_or_hot":-1,"title":"BRIEF-FDA Grants Priority Review for Biologics License Application (BLA) and EMA Accepts Marketing Authorisation Application (MAA) for Apitegromab as a Treatment for Spinal Muscular Atrophy","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-FDA Grants Priority Review for Biologics License Application <a href=\"https://laohu8.com/S/BLA.AU\">$(BLA.AU)$</a> and EMA Accepts Marketing Authorisation Application <a href=\"https://laohu8.com/S/MAA\">$(MAA)$</a> for Apitegromab as a Treatment for Spinal Muscular Atrophy</title></head><body><p><span>March 25 (Reuters)</span><span> - </span><a href=\"https://laohu8.com/S/SRRK\">Scholar Rock Holding Corp</a> <span>SRRK.O</span>:</p><ul><li><p>FDA GRANTS PRIORITY REVIEW FOR BIOLOGICS LICENSE APPLICATION (BLA) AND EMA ACCEPTS MARKETING AUTHORISATION APPLICATION (MAA) FOR APITEGROMAB AS A TREATMENT FOR SPINAL MUSCULAR ATROPHY</p></li><li><p>SCHOLAR ROCK HOLDING CORP - FDA PDUFA DATE FOR APITEGROMAB SET FOR SEPTEMBER 22, 2025</p></li><li><p>SCHOLAR ROCK HOLDING CORP - PLANS U.S. COMMERCIAL LAUNCH IN 2025</p></li></ul><p>Source text: <span>ID:nBw1KGRFLa</span></p><p>Further company coverage: <span>SRRK.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-FDA Grants Priority Review for Biologics License Application (BLA) and EMA Accepts Marketing Authorisation Application (MAA) for Apitegromab as a Treatment for Spinal Muscular Atrophy</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-FDA Grants Priority Review for Biologics License Application (BLA) and EMA Accepts Marketing Authorisation Application (MAA) for Apitegromab as a Treatment for Spinal Muscular Atrophy\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-03-25 19:33</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-FDA Grants Priority Review for Biologics License Application <a href=\"https://laohu8.com/S/BLA.AU\">$(BLA.AU)$</a> and EMA Accepts Marketing Authorisation Application <a href=\"https://laohu8.com/S/MAA\">$(MAA)$</a> for Apitegromab as a Treatment for Spinal Muscular Atrophy</title></head><body><p><span>March 25 (Reuters)</span><span> - </span><a href=\"https://laohu8.com/S/SRRK\">Scholar Rock Holding Corp</a> <span>SRRK.O</span>:</p><ul><li><p>FDA GRANTS PRIORITY REVIEW FOR BIOLOGICS LICENSE APPLICATION (BLA) AND EMA ACCEPTS MARKETING AUTHORISATION APPLICATION (MAA) FOR APITEGROMAB AS A TREATMENT FOR SPINAL MUSCULAR ATROPHY</p></li><li><p>SCHOLAR ROCK HOLDING CORP - FDA PDUFA DATE FOR APITEGROMAB SET FOR SEPTEMBER 22, 2025</p></li><li><p>SCHOLAR ROCK HOLDING CORP - PLANS U.S. COMMERCIAL LAUNCH IN 2025</p></li></ul><p>Source text: <span>ID:nBw1KGRFLa</span></p><p>Further company coverage: <span>SRRK.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250325:nTUA7WPWDB:1","article_id":"2522602952","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2522602952","pubTimestamp":1742902403,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-FDA Grants Priority Review for Biologics License Application (BLA) and EMA Accepts Marketing Authorisation Application (MAA) for Apitegromab as a Treatment for Spinal Muscular AtrophyMarch 25 (R","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","SRRK":"Scholar Rock Holding Corp"},"translate_title":"简介-FDA授予生物制品许可申请(BLA)优先审查，EMA接受Apitegromab治疗脊髓性肌萎缩症的上市许可申请(MAA)","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SRRK":0.9},"content_text":"BRIEF-FDA Grants Priority Review for Biologics License Application $(BLA.AU)$ and EMA Accepts Marketing Authorisation Application $(MAA)$ for Apitegromab as a Treatment for Spinal Muscular AtrophyMarch 25 (Reuters) - Scholar Rock Holding Corp SRRK.O:FDA GRANTS PRIORITY REVIEW FOR BIOLOGICS LICENSE APPLICATION (BLA) AND EMA ACCEPTS MARKETING AUTHORISATION APPLICATION (MAA) FOR APITEGROMAB AS A TREATMENT FOR SPINAL MUSCULAR ATROPHYSCHOLAR ROCK HOLDING CORP - FDA PDUFA DATE FOR APITEGROMAB SET FOR SEPTEMBER 22, 2025SCHOLAR ROCK HOLDING CORP - PLANS U.S. COMMERCIAL LAUNCH IN 2025Source text: ID:nBw1KGRFLaFurther company coverage: SRRK.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"code":"91000000","status":"200"}}}